Day One Biopharmaceuticals Inc (DAWN) concluded trading on Thursday at a closing price of $14.72, with 4.07 million shares of worth about $59.93 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.22% during that period and on October 31, 2024 the price saw a gain of about 1.73%. Currently the company’s common shares owned by public are about 87.23M shares, out of which, 59.32M shares are available for trading.
Stock saw a price change of 1.73% in past 5 days and over the past one month there was a price change of 8.08%. Year-to-date (YTD), DAWN shares are showing a performance of 0.82% which increased to 24.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.90 but also hit the highest price of $18.07 during that period. The average intraday trading volume for Day One Biopharmaceuticals Inc shares is 958.08K. The stock is currently trading 2.27% above its 20-day simple moving average (SMA20), while that difference is up 3.82% for SMA50 and it goes to 0.79% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) currently have 87.23M outstanding shares and institutions hold larger chunk of about 73.68% of that.
The stock has a current market capitalization of $1.29B and its 3Y-monthly beta is at -1.52. It has posted earnings per share of -$1.93 in the same period. It has Quick Ratio of 4.09 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DAWN, volatility over the week remained 5.91% while standing at 4.78% over the month.
Stock’s fiscal year EPS is expected to rise by 61.04% while it is estimated to decrease by -37.12% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on October 09, 2024 offering a Buy rating for the stock and assigned a target price range of between $32 and $33 to it. Coverage by BofA Securities stated Day One Biopharmaceuticals Inc (DAWN) stock as a Buy in their note to investors on August 01, 2024, suggesting a price target of $24 for the stock. On April 24, 2024, Needham Reiterated their recommendations, while on April 25, 2023, BofA Securities Downgrade their ratings for the stock with a price target of $9. Stock get an Overweight rating from CapitalOne on February 08, 2023.
